Shilpa Biologicals, a full-service CDMO, opened a dedicated bioconjugation suite at its Dharwad, India site. The suite is currently undergoing validation and is expected to begin onboarding client programs by September 2025.

The new multi-client bioconjugation suite is built to support the manufacture of ADCs and other advanced bioconjugates. It includes 200L single-use bioconjugation reactors and a lyophilization capacity of up to 65 kg. 

Complementary development laboratories will provide process development, analytical characterization, and early and late-stage scale-up capabilities. For final dose requirements, Shilpa’s Hyderabad site is also equipped with multiple isolator-based fill-finish lines dedicated to cytotoxic products.

The facility is located next to the company’s existing commercial biologics manufacturing facility.

This latest expansion positions Shilpa Biologicals among a select group of global CDMOs capable of providing clinical and commercial-scale manufacturing across three core antibody-drug conjugate (ADC) components.

Shilpa Biologicals, Chief Executive Officer Dr. Sridevi Khambhampaty commented, “Our co-located ADC services — spanning payloads, linkers, antibodies, and bioconjugation — are generating significant industry interest, especially from US and European biotech companies seeking a single, reliable partner to support their journey from discovery to commercial launch.”